PPARA and susceptibility to pneumonia measurement: Interestingly, while fenofibrates (PPARα agonist) are prescribed for abnormal blood lipid levels, infection and pneumonia are cited as possible adverse side effects (FDA, 2008; FDA, 2010) and fenofibrate has been associated with higher risk of mortality in MTB infections (Liu et al., 2020).